Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma

Conversy, Bérénice; Blais, Marie‐Claude; Dunn, Marilyn; Gara-Boivin, Carolyn; Carioto, Lisa; Castillo, J

doi:10.1016/j.tvjl.2013.08.001

Cited by 20 publications

(36 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No data regarding appropriate length of storage is reported in the human literature. In previous veterinary studies, sample storage times ranged from 2 to 31 months . Based on the present study, plasma samples for CAT appear to be stable at −80°C for at least 12 months.…”

Section: Discussionmentioning

confidence: 52%

Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs

Cuq

Blois

Wood

et al. 2018

Veterinary Clinical Pathol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 52%

Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs

Cuq

Blois

Wood

et al. 2018

Veterinary Clinical Pathol

View full text Add to dashboard Cite

show abstract

“…In people and in a recent in vitro study on canine plasma, antifactor Xa activity appears to be the test of choice in monitoring RIV therapy because of its better sensitivity and accuracy compared to PT, aPTT, and other coagulation assays . Therefore, in the present study the lack of significant prolongation of PT and aPTT does not necessarily indicate a lack of pharmacodynamic effect in these patients, as it could be due to the low sensitivity of these tests.…”

Section: Discussionmentioning

confidence: 68%

Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune‐mediated hemolytic anemia

Morassi

Bianco²,

Park

et al. 2016

J Vet Emergen Crit Care

View full text Add to dashboard Cite

This study suggests that RIV at a median dose of 0.89 mg/kg by mouth once daily was safe and well tolerated in a small group of dogs with presumed pIMHA able to tolerate oral medications and treated with a standardized immunosuppressive treatment protocol. Conclusions regarding the relative efficacy of RIV as compared to CL and LDA cannot be made due to the small size of the treatment groups and because pharmacodynamic effects were not assessed.

show abstract

“…This variation may have been affected by gastrointestinal drug absorption and genetic polymorphism in drug metabolism . Rivaroxaban has a lower affinity for canine factor Xa than for human factor Xa, and this difference may affect interindividual variability …”

Section: Discussionmentioning

confidence: 99%

“…Various commercial chromogenic anti‐Xa kits have been tested in veterinary medicine, and plasma anti‐Xa activity in dogs can be monitored accurately . Several chromogenic assays have been validated in humans and small animals for the evaluation of anti‐Xa activity for the quantification of rivaroxaban plasma concentration . A chromogenic assay was used in our study based on the methodology previously described .…”

Section: Discussionmentioning

confidence: 99%

Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time

Bae

Kim

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background The chromogenic anti‐Xa assay, the gold standard for monitoring the anti‐Xa effect of rivaroxaban, is not available as a cage‐side diagnostic test for use in a clinical setting. Hypothesis/Objectives To evaluate clinical modalities for measuring the anticoagulant effects of rivaroxaban using a point‐of‐care prothrombin time (PT) and thromboelastography (TEG). Animals Six healthy Beagle dogs. Methods Prospective, experimental study. Four different doses of rivaroxaban (0.5, 1, 2, and 4 mg/kg) were administered PO to dogs. Single PO and 3 consecutive dosing regimens also were assessed. Plasma rivaroxaban concentration was determined using a chromogenic anti‐Xa assay, point‐of‐care PT, and TEG analysis with 4 activators (RapidTEG, 1 : 100 tissue factor [TF100], 1 : 3700 tissue factor [TF3700], and kaolin), and results were compared. Spearman correlation coefficients were calculated between ratios (peak to baseline PT; peak reaction time [R] of TEG to baseline [R] of TEG) and anti‐Xa concentration. Results Anti‐Xa concentration had a significant correlation with point‐of‐care PT (R = 0.82, P < .001) and RapidTEG‐TEG, TF100‐TEG, and TF3700‐TEG (R = 0.76, P < .001; R = 0.82, P < .001; and R = 0.83, P < .001, respectively). Conclusions and Clinical Importance Overall, a 1.5‐1.9 × delay in PT and R values of TEG 3 hours after rivaroxaban administration is required to achieve therapeutic anti‐Xa concentrations of rivaroxaban in canine plasma. The R values of TEG, specifically using tissue factors (RapidTEG, TF100, TF3700) and point‐of‐care PT for rivaroxaban can be used practically for therapeutic monitoring of rivaroxaban in dogs.

show abstract

Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma

Cited by 20 publications

References 33 publications

Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs

Reproducibility, stability, and biological variability of thrombin generation using calibrated automated thrombography in healthy dogs

Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune‐mediated hemolytic anemia

Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time

Contact Info

Product

Resources

About